Report: Trace Amounts Of Steroid Metabolite Found In Jon Jones’ UFC 232 VADA Test


Jon Jones recaptured the UFC Light Heavyweight Title with a third round TKO win over Alexander Gustafsson in the main event of UFC 232.

The newly crowned champion, who had failed many drug tests in the past, was tested by both the United States Ant-Doping Agency (USADA) and the Voluntary Anti-Doping Agency (VADA) in the lead up to UFC 232. The UFC had moved UFC 232 to Inglewood, California after the NSAC found an abnormality in Jones’ drug test and the CSAC required Jones to be tested by VADA in order to compete in the state.

Khabib Nurmagomedov To Bring Eagle FC Promotion To The United States In 2022

Jones did pass all USADA issued drug tests leading into the event, but a test that was done by VADA on the day of weigh-ins came back positive for a metabolite that was previously discovered in Jones’ system.

A report from MMA Fighting states that Jones had 33 picograms of 4-chloro-18-nor-17β-hydroxymethyl,17α-methyl-5α-androst-13-en-3α-ol (M3) (or DHMCT) in his system, which was collected from a urine sample provided by the fighter.

There is going to be no disciplinary action taken by the California State Athletic Commission (CSAC) against Jones because it is the same long term metabolite that was already discovered in Jones’ system.

CSAC Executive Director Andy Foster said the following to MMA Fighting about the drug test result:

“I spoke with the scientists. They stand by their original statement. Nothing has changed. We’ve already punished Jon Jones for the M3 metabolite, which is a long-term metabolite. There’s no grounds to charge somebody twice for the same violation.”

This news comes less than a week before Jones is expected to appear in front of the Nevada State Athletic Commission (NSAC) in an attempt to get a license to fight in the state, as he is expected to defend the light heavyweight title against Anthony Smith at UFC 235.

Get exclusive pro wrestling content on Fightful Select, our premium news service! Click here to learn more.
From The Web